These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27239032)

  • 1. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
    Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
    Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
    Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
    Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the eIF4A RNA helicase as an anti-neoplastic approach.
    Chu J; Pelletier J
    Biochim Biophys Acta; 2015 Jul; 1849(7):781-91. PubMed ID: 25234619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of small molecules targeting eIF4A.
    Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
    RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F.
    Chu J; Zhang W; Cencic R; O'Connor PBF; Robert F; Devine WG; Selznick A; Henkel T; Merrick WC; Brown LE; Baranov PV; Porco JA; Pelletier J
    Cell Rep; 2020 Feb; 30(8):2481-2488.e5. PubMed ID: 32101697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
    Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
    Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
    Iwasaki S; Floor SN; Ingolia NT
    Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
    Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
    Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
    J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the enhancement of eIF4A helicase activity by eIF4G.
    Oberer M; Marintchev A; Wagner G
    Genes Dev; 2005 Sep; 19(18):2212-23. PubMed ID: 16166382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.
    Tillotson J; Kedzior M; Guimarães L; Ross AB; Peters TL; Ambrose AJ; Schmidlin CJ; Zhang DD; Costa-Lotufo LV; Rodríguez AD; Schatz JH; Chapman E
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4082-4085. PubMed ID: 28757063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
    Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
    Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.
    Chu J; Cencic R; Wang W; Porco JA; Pelletier J
    Mol Cancer Ther; 2016 Jan; 15(1):136-41. PubMed ID: 26586722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A forward genetic screen identifies modifiers of rocaglate responsiveness.
    Shen L; Pugsley L; Cencic R; Wang H; Robert F; Naineni SK; Sahni A; Morin G; Zhang W; Nijnik A; Porco JA; Langlais D; Huang S; Pelletier J
    Sci Rep; 2021 Sep; 11(1):18516. PubMed ID: 34531456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of hippuristanol-resistant mutants reveals eIF4A1 dependencies within mRNA 5' leader regions.
    Steinberger J; Shen L; J Kiniry S; Naineni SK; Cencic R; Amiri M; Aboushawareb SAE; Chu J; Maïga RI; Yachnin BJ; Robert F; Sonenberg N; Baranov PV; Pelletier J
    Nucleic Acids Res; 2020 Sep; 48(17):9521-9537. PubMed ID: 32766783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
    Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
    Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
    Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
    Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.
    Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH
    Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
    Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
    Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.